Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1999 Sep;75(887):516–520. doi: 10.1136/pgmj.75.887.516

Lambert-Eaton myasthenic syndrome

U Seneviratne 1, R de Silva 1
PMCID: PMC1741360  PMID: 10616683

Abstract

The Lambert-Eaton myasthenic syndrome is a neuromuscular disorder characterised by defective neurotransmitter release at autonomic neurones and presynaptic terminals of the neuromuscular junction. It is caused by an IgG autoantibody formed against especially the P/Q type of voltage-gated calcium channels (VGCC) which is an essential component of the mechanism of neurotransmitter release. Many patients have an associated small cell carcinoma of the lung which appears to provide the antigenic stimulus for antibody production, although there is another group with no underlying malignancy. Both groups show an association with immunological disorders. Assay of VGCC antibody titres and electrophysiological tests help to differentiate Lambert-Eaton myasthenic syndrome from other disorders of the neuromuscular junction. Several drugs and therapeutic interventions capable of producing significant clinical improvement are currently available. Patients should also be investigated for underlying tumours, the specific treatment of which can result in remission or amelioration of symptoms.


Keywords: Lambert-Eaton myasthenic syndrome; voltage-gated calcium channels

Full Text

The Full Text of this article is available as a PDF (78.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDERSON H. J., CHURCHILL-DAVIDSON H. C., RICHARDSON A. T. Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine. Lancet. 1953 Dec 19;265(6799):1291–1293. doi: 10.1016/s0140-6736(53)91358-0. [DOI] [PubMed] [Google Scholar]
  2. Agarawal S. K., Birch B. R., Abercrombie G. F. Adenocarcinoma of the prostate and Eaton-Lambert syndrome. A previously unreported association. Scand J Urol Nephrol. 1995 Sep;29(3):351–353. doi: 10.3109/00365599509180590. [DOI] [PubMed] [Google Scholar]
  3. Argov Z., Shapira Y., Averbuch-Heller L., Wirguin I. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve. 1995 Jul;18(7):715–719. doi: 10.1002/mus.880180707. [DOI] [PubMed] [Google Scholar]
  4. Bain P. G., Motomura M., Newsom-Davis J., Misbah S. A., Chapel H. M., Lee M. L., Vincent A., Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996 Sep;47(3):678–683. doi: 10.1212/wnl.47.3.678. [DOI] [PubMed] [Google Scholar]
  5. Bird S. J. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology. 1992 Jul;42(7):1422–1423. doi: 10.1212/wnl.42.7.1422. [DOI] [PubMed] [Google Scholar]
  6. Bowersox S. S., Miljanich G. P., Sugiura Y., Li C., Nadasdi L., Hoffman B. B., Ramachandran J., Ko C. P. Differential blockade of voltage-sensitive calcium channels at the mouse neuromuscular junction by novel omega-conopeptides and omega-agatoxin-IVA. J Pharmacol Exp Ther. 1995 Apr;273(1):248–256. [PubMed] [Google Scholar]
  7. Brown J. C., Johns R. J. Diagnostic difficulties encountered in the myasthenic syndrome sometimes associated with carcinoma. J Neurol Neurosurg Psychiatry. 1974 Nov;37(11):1214–1224. doi: 10.1136/jnnp.37.11.1214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chalk C. H., Murray N. M., Newsom-Davis J., O'Neill J. H., Spiro S. G. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990 Oct;40(10):1552–1556. doi: 10.1212/wnl.40.10.1552. [DOI] [PubMed] [Google Scholar]
  9. Cherington M. Guanidine and germine in Eaton-Lambert syndrome. Neurology. 1976 Oct;26(10):944–946. doi: 10.1212/wnl.26.10.944. [DOI] [PubMed] [Google Scholar]
  10. Cornelio F., Antozzi C., Confalonieri P., Baggi F., Mantegazza R. Plasma treatment in diseases of the neuromuscular junction. Ann N Y Acad Sci. 1998 May 13;841:803–810. doi: 10.1111/j.1749-6632.1998.tb11021.x. [DOI] [PubMed] [Google Scholar]
  11. Dau P. C., Denys E. H. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol. 1982 Jun;11(6):570–575. doi: 10.1002/ana.410110604. [DOI] [PubMed] [Google Scholar]
  12. Deodhar A., Norden J., So Y., Bennett R. The association of systemic lupus erythematosus and Lambert-Eaton myasthenic syndrome. J Rheumatol. 1996 Jul;23(7):1292–1294. [PubMed] [Google Scholar]
  13. Dunlap K., Luebke J. I., Turner T. J. Exocytotic Ca2+ channels in mammalian central neurons. Trends Neurosci. 1995 Feb;18(2):89–98. [PubMed] [Google Scholar]
  14. EATON L. M., LAMBERT E. H. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc. 1957 Mar 30;163(13):1117–1124. doi: 10.1001/jama.1957.02970480021005. [DOI] [PubMed] [Google Scholar]
  15. Elmqvist D., Lambert E. H. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968 Oct;43(10):689–713. [PubMed] [Google Scholar]
  16. Gutmann L., Crosby T. W., Takamori M., Martin J. D. The Eaton-Lambert syndrome and autoimmune disorders. Am J Med. 1972 Sep;53(3):354–356. doi: 10.1016/0002-9343(72)90179-9. [DOI] [PubMed] [Google Scholar]
  17. Gutmann L., Phillips L. H., 2nd, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology. 1992 Apr;42(4):848–850. doi: 10.1212/wnl.42.4.848. [DOI] [PubMed] [Google Scholar]
  18. Hawley R. J., Cohen M. H., Saini N., Armbrustmacher V. W. The carcinomatous neuromyopathy of oat cell lung cancer. Ann Neurol. 1980 Jan;7(1):65–72. doi: 10.1002/ana.410070112. [DOI] [PubMed] [Google Scholar]
  19. Heath J. P., Ewing D. J., Cull R. E. Abnormalities of autonomic function in the Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1988 Mar;51(3):436–439. doi: 10.1136/jnnp.51.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Henriksson K. G., Nilsson O., Rosén I., Schiller H. H. Clinical, neurophysiological and morphological findings in Eaton Lambert syndrome. Acta Neurol Scand. 1977 Aug;56(2):117–140. doi: 10.1111/j.1600-0404.1977.tb01417.x. [DOI] [PubMed] [Google Scholar]
  21. Hong S. J., Chang C. C. Inhibition of acetylcholine release from mouse motor nerve by a P-type calcium channel blocker, omega-agatoxin IVA. J Physiol. 1995 Jan 15;482(Pt 2):283–290. doi: 10.1113/jphysiol.1995.sp020517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jablecki C. Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1984 Mar-Apr;7(3):250–257. doi: 10.1002/mus.880070311. [DOI] [PubMed] [Google Scholar]
  23. Jenkyn L. R., Brooks P. L., Forcier R. J., Maurer L. H., Ochoa J. Remission of the Lambert-Eaton syndrome and small cell anaplastic carcinoma of the lung induced by chemotherapy and radiotherapy. Cancer. 1980 Sep 1;46(5):1123–1127. doi: 10.1002/1097-0142(19800901)46:5<1123::aid-cncr2820460508>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  24. Keesey J. C. AAEE Minimonograph #33: electrodiagnostic approach to defects of neuromuscular transmission. Muscle Nerve. 1989 Aug;12(8):613–626. doi: 10.1002/mus.880120802. [DOI] [PubMed] [Google Scholar]
  25. Khurana R. K., Koski C. L., Mayer R. F. Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1988 May;85(1):77–86. doi: 10.1016/0022-510x(88)90037-8. [DOI] [PubMed] [Google Scholar]
  26. Kim Y. I., Neher E. IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science. 1988 Jan 22;239(4838):405–408. doi: 10.1126/science.2447652. [DOI] [PubMed] [Google Scholar]
  27. Lambert E. H. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann N Y Acad Sci. 1966 Jan 26;135(1):367–384. doi: 10.1111/j.1749-6632.1966.tb45484.x. [DOI] [PubMed] [Google Scholar]
  28. Lambert E. H., Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci. 1971 Sep 15;183:183–199. doi: 10.1111/j.1749-6632.1971.tb30750.x. [DOI] [PubMed] [Google Scholar]
  29. Lemos J. R., Nowycky M. C. Two types of calcium channels coexist in peptide-releasing vertebrate nerve terminals. Neuron. 1989 May;2(5):1419–1426. doi: 10.1016/0896-6273(89)90187-6. [DOI] [PubMed] [Google Scholar]
  30. Lennon V. A., Kryzer T. J., Griesmann G. E., O'Suilleabhain P. E., Windebank A. J., Woppmann A., Miljanich G. P., Lambert E. H. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995 Jun 1;332(22):1467–1474. doi: 10.1056/NEJM199506013322203. [DOI] [PubMed] [Google Scholar]
  31. Lennon V. A., Lambert E. H., Whittingham S., Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1982;5(9S):S21–S25. [PubMed] [Google Scholar]
  32. Lundh H., Nilsson O., Rosén I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology. 1984 Oct;34(10):1324–1330. doi: 10.1212/wnl.34.10.1324. [DOI] [PubMed] [Google Scholar]
  33. Maselli R. A. Electrodiagnosis of disorders of neuromuscular transmission. Ann N Y Acad Sci. 1998 May 13;841:696–711. doi: 10.1111/j.1749-6632.1998.tb11005.x. [DOI] [PubMed] [Google Scholar]
  34. Maselli R. A., Mass D. P., Distad B. J., Richman D. P. Anconeus muscle: a human muscle preparation suitable for in-vitro microelectrode studies. Muscle Nerve. 1991 Dec;14(12):1189–1192. doi: 10.1002/mus.880141208. [DOI] [PubMed] [Google Scholar]
  35. McEvoy K. M., Windebank A. J., Daube J. R., Low P. A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989 Dec 7;321(23):1567–1571. doi: 10.1056/NEJM198912073212303. [DOI] [PubMed] [Google Scholar]
  36. Meriney S. D., Hulsizer S. C., Lennon V. A., Grinnell A. D. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol. 1996 Nov;40(5):739–749. doi: 10.1002/ana.410400510. [DOI] [PubMed] [Google Scholar]
  37. Molgó J., Lundh H., Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol. 1980 Jan 11;61(1):25–34. doi: 10.1016/0014-2999(80)90378-7. [DOI] [PubMed] [Google Scholar]
  38. Motomura M., Lang B., Johnston I., Palace J., Vincent A., Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997 Mar 20;147(1):35–42. doi: 10.1016/s0022-510x(96)05303-8. [DOI] [PubMed] [Google Scholar]
  39. Newsom-Davis J. A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 1998 May 13;841:817–822. doi: 10.1111/j.1749-6632.1998.tb11023.x. [DOI] [PubMed] [Google Scholar]
  40. Newsom-Davis J., Murray N. M. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984 Apr;34(4):480–485. doi: 10.1212/wnl.34.4.480. [DOI] [PubMed] [Google Scholar]
  41. O'Neill J. H., Murray N. M., Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988 Jun;111(Pt 3):577–596. doi: 10.1093/brain/111.3.577. [DOI] [PubMed] [Google Scholar]
  42. O S. J., Kim K. W. Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement. Neurology. 1973 Oct;23(10):1084–1090. doi: 10.1212/wnl.23.10.1084. [DOI] [PubMed] [Google Scholar]
  43. Oguro-Okano M., Griesmann G. E., Wieben E. D., Slaymaker S. J., Snutch T. P., Lennon V. A. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc. 1992 Dec;67(12):1150–1159. doi: 10.1016/s0025-6196(12)61144-6. [DOI] [PubMed] [Google Scholar]
  44. Oh S. J., Kim D. S., Head T. C., Claussen G. C. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1997 Sep;20(9):1146–1152. doi: 10.1002/(sici)1097-4598(199709)20:9<1146::aid-mus9>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  45. Ozata M., Odabasi Z., Musabak U., Corakci A., Gundogan M. A. A case of Addison's disease associated with the Lambert-Eaton myasthenic syndrome. J Endocrinol Invest. 1997 Jun;20(6):338–341. doi: 10.1007/BF03350314. [DOI] [PubMed] [Google Scholar]
  46. Sanders D. B. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Ann N Y Acad Sci. 1998 May 13;841:811–816. doi: 10.1111/j.1749-6632.1998.tb11022.x. [DOI] [PubMed] [Google Scholar]
  47. Schwartz M. S., Stålberg E. Myasthenic syndrome studied with single fiber electromyography. Arch Neurol. 1975 Dec;32(12):815–817. doi: 10.1001/archneur.1975.00490540059007. [DOI] [PubMed] [Google Scholar]
  48. Snutch T. P., Reiner P. B. Ca2+ channels: diversity of form and function. Curr Opin Neurobiol. 1992 Jun;2(3):247–253. doi: 10.1016/0959-4388(92)90111-w. [DOI] [PubMed] [Google Scholar]
  49. Takano H., Tanaka M., Koike R., Nagai H., Arakawa M., Tsuji S. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve. 1994 Sep;17(9):1073–1075. doi: 10.1002/mus.880170919. [DOI] [PubMed] [Google Scholar]
  50. Tsuchiya N., Sato M., Uesaka Y., Kurose N., Haida M., Nakano J., Tsuchida T., Inoue T., Ito K. Lambert-Eaton myasthenic syndrome associated with Sjögren's syndrome and discoid lupus erythematosus. Scand J Rheumatol. 1993;22(6):302–304. doi: 10.3109/03009749309095144. [DOI] [PubMed] [Google Scholar]
  51. Varadi G., Mori Y., Mikala G., Schwartz A. Molecular determinants of Ca2+ channel function and drug action. Trends Pharmacol Sci. 1995 Feb;16(2):43–49. doi: 10.1016/s0165-6147(00)88977-4. [DOI] [PubMed] [Google Scholar]
  52. Vincent A., Lang B., Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989 Dec;12(12):496–502. doi: 10.1016/0166-2236(89)90109-4. [DOI] [PubMed] [Google Scholar]
  53. Volsen S. G., Day N. C., McCormack A. L., Smith W., Craig P. J., Beattie R. E., Smith D., Ince P. G., Shaw P. J., Ellis S. B. The expression of voltage-dependent calcium channel beta subunits in human cerebellum. Neuroscience. 1997 Sep;80(1):161–174. doi: 10.1016/s0306-4522(97)00115-2. [DOI] [PubMed] [Google Scholar]
  54. Waterman S. A., Lang B., Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol. 1997 Aug;42(2):147–156. doi: 10.1002/ana.410420204. [DOI] [PubMed] [Google Scholar]
  55. Waterman S. A. Multiple subtypes of voltage-gated calcium channel mediate transmitter release from parasympathetic neurons in the mouse bladder. J Neurosci. 1996 Jul 1;16(13):4155–4161. doi: 10.1523/JNEUROSCI.16-13-04155.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Waterman S. A. Role of N-, P- and Q-type voltage-gated calcium channels in transmitter release from sympathetic neurones in the mouse isolated vas deferens. Br J Pharmacol. 1997 Feb;120(3):393–398. doi: 10.1038/sj.bjp.0700948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Willcox N., Demaine A. G., Newsom-Davis J., Welsh K. I., Robb S. A., Spiro S. G. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum Immunol. 1985 Sep;14(1):29–36. doi: 10.1016/0198-8859(85)90062-x. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES